GlassScriptPhysician profile
Melissa A Davis
NPI 1497480917
$835.93
in general payments reported to CMS, 2019-2025
19 companies · $82.04 in 2025
The $82.04 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $88.50 · 2023: $602 · 2024: $63.43 · 2025: $82.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.43 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $143.66 | 2022-2023 | Imbruvica, Epkinly |
| Incyte Corporation | $121.35 | 2023 | Pemazyre, Monjuvi |
| Pfizer INC. | $83.94 | 2023 | |
| Merck Sharp & Dohme LLC | $71.67 | 2022-2023 | Keytruda, Welireg, Lynparza |
| Beigene USA, INC. | $64.24 | 2022-2023 | Brukinsa |
| Abbvie INC. | $57.51 | 2023-2025 | |
| Organon LLC | $55.67 | 2024-2025 | Nexplanon |
| Novartis Pharmaceuticals Corporation | $55.59 | 2023-2024 | |
| Janssen Biotech, INC. | $24.10 | 2023 | Erleada |
| Novocure INC. | $20.16 | 2023 | Optune |
| Exact Sciences Corporation | $18.06 | 2025 | Cologuard Collection Kit |
| Coherus Oncology, INC. | $17.51 | 2023 | |
| Hologic Sales and Service, LLC | $16.86 | 2024 | Aptima, Thinprep 2000 Processor |
| Glaxosmithkline, LLC. | $16.31 | 2023 | Ojjaara |
| Amgen INC. | $14.92 | 2025 | Evenity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $14.04 | 2023 | Vonjo |
| Celgene Corporation | $13.91 | 2023 | Reblozyl |
| Seagen INC. | $13.48 | 2023 | Tukysa |
| Karyopharm Therapeutics INC. | $12.95 | 2023 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.